Fiscal Year Earnings Estimate on Threshold Pharmaceuticals, Inc.(THLD)

Threshold Pharmaceuticals, Inc.(THLD): For the most recent quarter end, Threshold Pharmaceuticals, Inc. reported Annual Earnings of $-0.08. Based on the filings, last years Annual Earnings was, $0.3. For the most recent quarter end, THLD reported a surprise Earnings per Share of 11.11% . The consensus estimate for current quarter is $-0.08 and for the current fiscal year, the estimate is $-0.4. For the Next fiscal year, the estimate is $-0.36 based on the consensus. South San Francisco based Threshold Pharmaceuticals, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 09, 2017.

Threshold Pharmaceuticals, Inc. has received $-0.08 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.08 while the top line estimate is $-0.07 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -112.1%. Threshold Pharmaceuticals, Inc. reported better than expected with a surprise EPS of 11.11% or $0.01 during its most recent quarterly earnings. The Actual EPS was $-0.08 compared to the Estimated EPS of $-0.09. According to the corporate earnings calendar, Threshold Pharmaceuticals, Inc. will release next earnings on Mar 09, 2017 with an estimated EPS consensus of $-0.08. Based on the consensus of stock financial advisors the stock has a price target of $0.7. Current year estimate on EPS consensus is $-0.4.

For Dividend Investing Stock Market Traders Threshold Pharmaceuticals, Inc. has a Dividend Yield of 0% with an Annual Dividend of $0. It has a Payout Ratio of 0 and the change in Dividend payout ratio is .

Company has reported several Insider transactions to the SEC, on Apr 29, 2016, Joel A Fernandes (Senior Vice President) purchased 3,562 shares at 3.96 per share price.On Feb 20, 2015, Wilfred E Jaeger (director) purchased 25,000 shares at 3.74 per share price.

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) witnessed a decline in the market cap on Wednesday as its shares dropped 3.98% or 0.0251 points. After the session commenced at $0.626, the stock reached the higher end at $0.6422 while it hit a low of $0.5979. With the volume soaring to 870,026 shares, the last trade was called at $0.6049. The company has a 52-week high of $1.48. The company has a market cap of $43 million and there are 71,560,294 shares in outstanding. The 52-week low of the share price is $0.21.

Threshold is focused on the discovery, development, and commercialization of small molecule therapeutics based on Metabolic Targeting. This approach targets abnormal glucose metabolism – a fundamental property of most solid tumors and other diseases. The companys initial focus is the treatment of cancer and benign prostatic hyperplasia, a disease characterized by overgrowth of the prostate.


Add Comment